Disc Medicine, Inc. (NASDAQ: IRON) is thrilled to announce the exciting news of its outlook for the future as it dives into the world of biopharmaceuticals. The company, focused on the development and commercialization of treatments to help patients suffering from serious hematologic diseases, has priced its upsized underwritten public offering of shares of common stock and pre-funded warrants. An impressive 2,595,919 shares of common stock and pre-funded warrants to purchase 204,081 shares of common stock have been offered.
With an offering price of $49.00 per share and a pre-funded warrant offering price of $48.9999 per pre-funded warrant, the aggregate gross proceeds to Disc from this offering are expected to be $137.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
To add even more potential to the mix, Disc has granted the underwriters a 30-day option to purchase a maximum of 420,000 additional shares of its common stock at a discounted rate. With all the offering closing conditions satisfied, the offering is expected to close on June 16, 2023.
BioDisc is proud to announce its offering that will provide the resources needed to further their research and clinical development endeavors and allow for general corporate purposes. These proceeds will bring them one step closer to providing innovative product candidates to their valued customers.
The offering is being managed by a powerhouse team of financial services firms, including Morgan Stanley, SVB Securities, Stifel, and BMO Capital Markets as the joint book-running managers and Wedbush PacGrow as the lead manager. This dynamic group has the expertise needed to successfully launch the offering.
Disc is offering an exciting opportunity to invest in the securities described above, as they are being made available through a shelf registration statement on Form S-3 , that was successfully declared effective by the SEC on January 24, 2023. This offering is subject to a prospectus and prospectus supplement that are included in the registration statement. Act now and seize this opportunity while you still can!
About Disc Medicine
At Iron Disc Medicine, we are dedicated to providing promising solutions for patients with severe hematological diseases. Our aim is to create innovative and groundbreaking therapeutic treatments that target the underlying pathways of red blood cell biology. By targeting heme biosynthesis and iron homeostasis, we are looking forward to transforming the standard of care for sufferers of hematological diseases. With our commitment to delivering groundbreaking discoveries, Iron Disc Medicine is the future of hematology.
Cautionary Statement Regarding Forward-Looking Statements
Disc is excited to announce that we will soon be offering a public offering! This will create many interesting opportunities and chances for growth for our company. Risk factors that have to be taken into consideration include our stock price fluctuations, changes in market conditions, and other risks identified in our SEC filings.
We believe that this offering could lead to significant progress for Disc and are confident that we have taken the right steps to ensure a successful outcome. With that in mind, Disc urges all investors to consider the risks and uncertainties involved in this offering before making any decisions.